Business
Spectral and Estor strengthen EAA(TM) market position in Italy
Spectral and Estor strengthen EAA(TM) market position in Italy.
About this update from Spectral Medical Inc
[{"type":"text","content":"\n\n\n\nTORONTO, May 16 /CNW/ - Spectral Diagnostics Inc. ("Spectral") today\nannounced a major expansion of its EAA(TM) product distribution in Italy with\nits partner Estor, SpA ("Estor"). The agreement will rapidly increase the\nnumber of hospitals in Italy utilizing the EAA(TM) assay and will dramatically\nexpand the market penetration and test usage in this important region. This\nimproved arrangement further strengthens Spectral's European market presence.\n\n\n"Italy has been an important region for the growth of EAA(TM) sales in\nEurope. This broad introduction of the EAA(TM) assay will build a critical\nmass for test sales that will help establish EAA(TM) as the premier diagnostic\nfor Endotoxemia related diseases," stated Dr. Paul Walker, President & CEO of\nSpectral.\n\n\nEstor, a leading supplier of in vitro diagnostic technologies in Italy,\nwill distribute Spectral's new assay instrument and its reagents for use in\nemergency departments and intensive care units. Estor is also the exclusive\ndistributor of Toray Medical's endotoxin removal system in Italy. Spectral\nentered into a combined diagnostic and therapeutic strategic alliance with\nToray last year for the management of severe sepsis.\n\n\nSpectral is a developer of innovative technologies for rapid diagnostics.\nSpectral provides accurate and timely information to clinicians enabling the\nearly initiation of appropriate and targeted therapy. Current products include\nrapid diagnostics for sepsis (EAA(TM)) and West Nile Virus as well as a range\nof other biological reagents. Spectral's common shares are listed on The\nToronto Stock Exchange: SDI.\n\n\nInformation in this news release that is not current or historically\nfactual information may constitute forward-looking information within the\nmeaning of securities laws. Implicit in this information, the future outlook\nof Spectral and anticipated events or results are assumptions based on beliefs\nof Spectral's senior management as well as information currently available to\nit. While these assumptions were considered reasonable by Spectral at the time\nof preparation, they may prove to be incorrect. Readers are cautioned that\nactual results are subject to a number of risks and uncertainties, including\nthe availability of funds and resources to pursue R&D projects, t...